CARVYKTI achieves five-year treatment-free remission in 50% of early-line myeloma patients

CARVYKTI (cilta-cel) achieved five-year treatment-free remission in 50% of early-line relapsed or refractory multiple myeloma patients in a Phase 2 study, providing a durable benefit not previously seen with single treatments in myeloma. This data supports expanding use of CARVYKTI earlier in treatment sequences, pending confirmation from larger cohorts.

This Wire brief sits within Fusion42's coverage of Biotech.